Structural heart disease implant developer Occlutech said today it won CE Mark approval in the European Union for its Left Atrial Appendix occluder device designed for the minimally invasive closure of the LAA to reduce the risk of stroke in patients with atrial fibrillation.
The Occlutech LAA occluder device consists of a flexible nitinol wire mesh and loop anchoring and sealing technology, the Swiss company said.
“We are extremely pleased to be able to provide patients and cardiologists with this innovative product and expect our LAA occluder to significantly add and improve therapy options for patients,” CEO Tor Peters said in prepared remarks.
The company touts that the device “provides properties that enhance flexibility and adaptability resulting in a high rate of acute closure.”
Last September, Occlutech said it won CE Mark approval in the European Union for its ventricle septal defect closure device. The implantable device will be available in different configurations and sizes and can accommodate a range of ventricle septal defects, the company said.